Trials / Unknown
UnknownNCT06125171
Tucidinostat Plus Apatinib for Advanced Osteosarcoma
A Phase II Clinical Trial of Tucidinostat in Combination With Apatinib in Patients With Relapsed or Refractory Osteosarcoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
- Sex
- All
- Age
- 10 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This phase II study was designed to assess the efficacy and safety of the combination of Apatinib, Tucidinostat (chidamide), a histone deacetylase inhibitor in relapsed or refractory osteosarcoma patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tucidinostat, Apatinib | Tucidinostat: age≥18years, 30mg, po., biw, q4w; age≥10years，\<18years，0.5mg/kg, biw, q4w Apatinib: BSA≥1.2m\^2, 500mg, qd, q4w BSA\<1.2m\^2, 250mg, qd, q4w |
Timeline
- Start date
- 2024-01-01
- Primary completion
- 2024-12-01
- Completion
- 2025-12-01
- First posted
- 2023-11-09
- Last updated
- 2023-11-09
Source: ClinicalTrials.gov record NCT06125171. Inclusion in this directory is not an endorsement.